GlassScriptPhysician profile
Marc A Antonchak
NPI 1982893103
$10,290.92
in general payments reported to CMS, 2019-2025
21 companies · $3,013 in 2025
The $3,013 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $347 · 2021: $520 · 2022: $1,273 · 2023: $2,055 · 2024: $2,532 · 2025: $3,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,547 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,547.01 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,518.26 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,785.74 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,315.38 | 2019-2025 | |
| Janssen Biotech, INC. | $881.55 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $494.56 | 2019-2025 | |
| Horizon Therapeutics Plc | $432.83 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $378.80 | 2019-2023 | Actemra, Rituxan, Enspryng |
| Ucb, INC. | $303.33 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $223.38 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $217.17 | 2022-2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $202.62 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $109.31 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $101.03 | 2019-2021 | |
| Organon LLC | $94.24 | 2024-2025 | Hadlima |
| Octapharma USA, INC. | $55.21 | 2023-2025 | Octagam Immune Globulin (Human) |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $53.45 | 2025 | |
| Genzyme Corporation | $52.67 | 2023-2025 | |
| Sobi, INC | $30.03 | 2024-2025 | |
| Sandoz INC. | $15.81 | 2023 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $14.49 | 2019 | |
| Neurometrix INC | $11.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Antonchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.